Alpha-lipoic acid for weight loss: what the evidence shows

2. Why ALA is promoted for weight loss

The weight-loss pitch mostly comes from plausible biology. In cell and animal studies, ALA has been linked with glucose uptake, insulin signalling, inflammation, oxidative stress and AMPK, an enzyme involved in sensing the body’s energy status.

One influential rodent study found that ALA reduced hypothalamic AMPK activity, lowered food intake, increased energy expenditure and produced major weight loss. On paper, that looks like a tidy “eat less, burn more” mechanism. The catch is that rodent brain and appetite findings often do not translate neatly to humans taking oral supplements.

There are practical reasons the effect may be modest, too. Oral ALA has limited bioavailability, often estimated around 20 to 40 percent, and different forms may behave differently. Common supplements contain a mixture of R- and S-alpha-lipoic acid, while some trials use the R-form alone. A promising mechanism does not guarantee a strong real-world result.

3. What randomized trials and reviews show

The most useful view comes from looking across randomized controlled trials. Recent meta-analyses generally find that ALA can nudge the scale slightly, but not dramatically.

• A large 2025 dose-response meta-analysis of 63 randomized trials reported average reductions of about 0.64 kg in body weight, 0.27 kg/m² in BMI, 1.10 cm in waist circumference and 1.42 kg in fat mass. It also found modest improvements in fasting glucose, fasting insulin, HOMA-IR, HbA1c, triglycerides and total cholesterol.
• Earlier reviews found similar small effects. One meta-analysis reported about 0.69 kg lower body weight and 0.38 kg/m² lower BMI versus placebo, with no significant overall waist reduction. Another estimated 1.27 kg greater weight loss than placebo.
• A 2025 review focused specifically on adults with overweight or obesity found no significant effect on triglycerides, cholesterol fractions, fasting glucose or HOMA-IR. That makes the common claim that ALA broadly “improves metabolism” in otherwise typical adults carrying excess weight harder to support.

Individual trials tell a similar story. In a 24-week trial of 81 overweight or obese adults, 600 mg/day of R-alpha-lipoic acid led to about 1.7 kg of weight loss and a BMI reduction of about 0.6. In a larger 20-week trial of 360 adults with obesity, only the 1,800 mg/day group lost significantly more weight than placebo, and the effect was about 2.1 percent of body weight.

These changes are measurable in studies. They are also modest. The NIDDK describes losing about 5 percent of body weight over 6 months as a reasonable initial goal in obesity treatment. Most ALA effects fall well below that benchmark.

4. Body composition, waist and appetite

ALA’s effects on body composition are less convincing than its small effect on body weight. Waist circumference findings are mixed: some reviews find no significant overall change, while others find small reductions or signals in certain subgroups. Fat mass data are more limited, although the broad 2025 meta-analysis did report an average reduction.

The appetite evidence is thinner still. A 12-week trial in stroke patients found that 600 mg/day reduced waist circumference and reported intake of energy, carbohydrate, protein and fat, but did not reduce body weight or BMI. That is interesting, but it does not prove appetite suppression in the general public.

Biomarkers can also look more impressive than the day-to-day outcome. ALA appears to lower leptin and raise adiponectin in some analyses. In theory, these hormones are tied to appetite, fat tissue and insulin sensitivity. In practice, a shift in a blood marker does not automatically mean visible body-fat loss. A trial in obese adults with non-alcoholic fatty liver disease found changes in insulin, leptin and adiponectin without meaningful differences in anthropometric or body-composition outcomes.

This is a common pattern in supplement research. Ingredients such as green tea extract can show small body-composition signals without acting like a true fat-loss treatment.

5. Who might respond better?

Some studies suggest the response may not be the same for everyone. In the 24-week R-alpha-lipoic acid trial, women and participants with BMI of at least 35 appeared to lose more weight and body fat than the overall group. A trial in overweight or obese women on a calorie-restricted diet found that adding 300 mg/day ALA led to greater weight loss than diet control.

Some reviews have also suggested that waist results may differ by sex, metabolic health or study duration. ALA has been explored in medication-related weight-gain settings too, but subgroup findings remain too uncertain for targeted recommendations.

The most practical reading is this: ALA may work a little better in some groups, or when paired with calorie restriction, but the evidence is not strong enough to treat it as a dependable fat-loss tool.

6. Practical considerations

Trials have used a wide range of doses, including 300, 600, 1,200 and 1,800 mg/day. The evidence does not show a simple “higher dose equals more fat loss” pattern. One meta-analysis found no significant relationship between dose and weight or BMI change, while duration seemed to affect BMI more than weight.

Higher doses may also be harder to tolerate. If someone chooses to try ALA, practical timing, dose and safety context matters. It is more realistic to see it as an experimental add-on to nutrition, activity, sleep and medical care — not a replacement for them.

The same caution applies across weight management supplements, including chromium and berberine: marketing often moves faster than the size of the effect.

7. Safety

ALA is generally well tolerated in many trials. Common side effects include headache, heartburn, nausea and vomiting. Mild itching or hives have also been reported, especially in higher-dose studies.

There is one rare but important safety issue: insulin autoimmune syndrome, a condition that can cause episodes of low blood sugar. The European Food Safety Authority reviewed case evidence and concluded that a risk-free dose could not be determined from available data.

People taking diabetes medication, people with a history of unexplained low blood sugar, pregnant or breastfeeding adults, and anyone managing a medical condition should speak with a clinician before using ALA. Weight-loss supplements can also distract from care that has stronger evidence.